Published in Thyroid on November 01, 2008
New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review. J Thyroid Res (2012) 0.84
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines. Eur J Nucl Med Mol Imaging (2008) 0.80
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol (2009) 2.67
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood (2013) 2.34
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 2.09
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood (2003) 1.99
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res (2006) 1.67
Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood (2004) 1.56
Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Cancer Biol Ther (2011) 1.45
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood (2004) 1.44
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood (2013) 1.42
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood (2003) 1.32
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32
Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med (2008) 1.31
CD63 tetraspanin slows down cell migration and translocates to the endosomal-lysosomal-MIICs route after extracellular stimuli in human immature dendritic cells. Blood (2004) 1.30
Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J Immunol (2002) 1.29
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood (2006) 1.27
Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin Cancer Res (2005) 1.19
The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol (2007) 1.18
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther (2011) 1.18
Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol (2006) 1.16
Retraction: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2003) 1.16
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol (2006) 1.14
hDectin-1 is involved in uptake and cross-presentation of cellular antigens. Blood (2007) 1.13
The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope (2005) 1.12
Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J (2007) 1.11
Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res (2007) 1.10
Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat (2011) 1.10
Human cytomegalovirus induces a direct inhibitory effect on antigen presentation by monocyte-derived immature dendritic cells. Br J Haematol (2002) 1.09
PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood (2005) 1.09
TLR ligands differentially affect uptake and presentation of cellular antigens. Blood (2007) 1.08
Dectin-1 interaction with tetraspanin CD37 inhibits IL-6 production. J Immunol (2007) 1.08
Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol (2007) 1.07
Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse. J Infect Dis (2012) 1.07
Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother (2010) 1.05
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res (2007) 1.03
Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res (2005) 1.03
The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood (2002) 1.03
Novel treatment concepts for graft-versus-host disease. Blood (2011) 1.02
Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.02
Diffusion-weighted magnetic resonance imaging of the pancreas: diagnostic benefit from an intravoxel incoherent motion model-based 3 b-value analysis. Invest Radiol (2014) 1.01
The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2006) 1.01
Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res (2007) 0.99
Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res (2004) 0.98
The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol (2006) 0.97
Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood (2003) 0.97
PET-CT evaluation of 2-deoxy-2-[18F]fluoro-D-glucose myocardial uptake: effect of respiratory motion. Mol Imaging Biol (2003) 0.96
Identification of a lysosomal peptide transport system induced during dendritic cell development. J Biol Chem (2007) 0.95
Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother (2009) 0.94
Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood (2002) 0.94
Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. Clin Cancer Res (2004) 0.94
18F-fluorobenzyl triphenyl phosphonium: a noninvasive sensor of brown adipose tissue thermogenesis. J Nucl Med (2011) 0.93
Role of peroxisome proliferator-activated receptor gamma and its ligands in the control of immune responses. Crit Rev Immunol (2003) 0.93
IL-4-mediated fine tuning of IL-12p70 production by human DC. Eur J Immunol (2008) 0.92
Molecular and functional characterization of human Dectin-1. Exp Hematol (2002) 0.92
Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells (2005) 0.92
Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. Blood (2008) 0.92
Autoimmunity as the most frequent cause of idiopathic secondary adrenal insufficiency: report of 111 cases. Autoimmunity (2003) 0.92
Dendritic cells in vaccination therapies of human malignant disease. Blood Rev (2004) 0.89
Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica (2003) 0.89
Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res (2004) 0.89
Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev (2007) 0.89
The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. Cancer Immunol Immunother (2011) 0.88
RNA vaccines in cancer treatment. J Biomed Biotechnol (2010) 0.87
Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin Cancer Res (2008) 0.87
Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal expansion and metaplasia in the adult murine pancreas. Neoplasia (2011) 0.87
Agents targeting the Hedgehog pathway for pancreatic cancer treatment. Curr Opin Investig Drugs (2010) 0.86
Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother (2009) 0.86
Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling. J Immunol (2003) 0.85
Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone. Blood (2011) 0.85
Increase of in vivo antitumoral activity by CD40L (CD154) gene transfer into pancreatic tumor cell-dendritic cell hybrids. Pancreas (2009) 0.85
Activation of invariant NK T cells in periodontitis lesions. J Immunol (2013) 0.85
[Analysis of Fas, FasL and Caspase-8 expression in thyroid gland in young patients with immune and non-immune thyroid diseases]. Endokrynol Pol (2007) 0.84
Immunotherapy in renal cell carcinoma. Immunotherapy (2009) 0.84
New developments in dendritic cell-based vaccinations: RNA translated into clinics. Cancer Immunol Immunother (2005) 0.84
Pendred syndrome in two Galician families: insights into clinical phenotypes through cellular, genetic, and molecular studies. J Clin Endocrinol Metab (2007) 0.84
A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. Clin Cancer Res (2012) 0.83
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Ann Hematol (2011) 0.83
Activated CD8+ T lymphocytes induce differentiation of monocytes to dendritic cells and restore the stimulatory capacity of interleukin 10-treated antigen-presenting cells. Cancer Res (2002) 0.83
The evaluation of FDG-PET imaging for epileptogenic focus localization in patients with MRI positive and MRI negative temporal lobe epilepsy. Neuroradiology (2012) 0.82
Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. Clin Cancer Res (2003) 0.82
Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells (2004) 0.82
Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Ther (2005) 0.82
Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells. Cancer Immunol Immunother (2008) 0.82
Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. Cancer Gene Ther (2003) 0.82
Discrepant uptake of the radiolabeled norepinephrine analogues hydroxyephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat hearts. Eur J Nucl Med Mol Imaging (2013) 0.82
Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides. Cancer Immunol Immunother (2012) 0.81
Isolated secondary adrenal insufficiency--an underestimated consequence of asymptomatic autoimmune hypophysitis. Clin Endocrinol (Oxf) (2011) 0.81
Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research. Expert Opin Drug Discov (2010) 0.81
Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-gamma-independent mechanism: regulation by inflammatory and T cell-derived stimuli. Exp Hematol (2002) 0.80
Humanized medium (h7H) allows long-term primary follicular thyroid cultures from human normal thyroid, benign neoplasm, and cancer. J Clin Endocrinol Metab (2013) 0.80
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines. Eur J Nucl Med Mol Imaging (2008) 0.80
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer (2005) 0.80
A redundant role of human thyroid peroxidase propeptide for cellular, enzymatic, and immunological activity. Thyroid (2013) 0.80
Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol (2003) 0.79
Acquired perforating collagenosis in Hodgkin's disease. J Am Acad Dermatol (2005) 0.79
BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res (2006) 0.79
Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia. Support Care Cancer (2015) 0.79
Regression of liver metastases after treatment with oxaliplatin/capecitabine and development of a progressive multifocal leukoencephalopathy in a patient with advanced thymoma. J Clin Oncol (2013) 0.78